10-q out...
-No revenues in Q3.
-For first time ever in a quarterly report, IMUN lists that they ARE HOLDING inventory: $214k in inventory. This is very positive IMO. Looks like revenues should indeed begin as expected in Q4. Or else, they wouldn't be holding inventory IMO.
- The full contract for Omaera is listed at the end of the 10-q. More detailed than the 9/8/17 8-k.
- The full securities purchase agreement with Iliad is listed in the 10-q. More detailed than the 11/2/17 8-k.
- Details about AHAR and Nigeria in 10-q...
"In September 2017, the Company became registered under the U.S. Government's System for Award Management to sell Lodonal TM to Nigeria through the United States Agency for International Development (“USAID”) and UNAIDS. At the same time, the Company and AHAR filed for regulatory approval of the use of Lodonal TM with the National Agency for the Control of AIDS in Nigeria (“NACA”). Once NACA approves the use of Lodonal TM as a treatment for AIDS, it will be able to purchase Lodonal TM directly from the Company and AHAR.
In addition to the work with NACA, USAID and UNAIDS, AHAR and the Company are moving forward with applications to NAFDAC to permit the sale of Lodonal™ in Nigeria for additional indications. They expect to submit those applications in the first quarter of 2018. Those indications include the use of the drug as an adjunct to treatment of chemotherapy, opportunistic infections and cancer."
-Www.aharpharma.com shows that you can add Lodonal to your cart already, but website still looks incomplete. Mentions Lodonal for cancer. Doesn't mention HIV. According to what the 10-q says, they shouldn't be mentioning HIV just quite yet. This website still needs work, but looks better than 2 months ago. Even though you can add Lodonal to your cart, who knows if it's actually being sold yet. I wouldn't count on it quite yet, but still this is forward progression.
